ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
Helix Biomedix Inc (PK)

Helix Biomedix Inc (PK) (HXBM)

12.00
-3.35
(-21.82%)
마감 18 12월 6:00AM

개인 투자자를 위한 전문가급 도구.

주요 통계 및 세부정보

가격
12.00
매수가
3.11
매도가
17.99
거래량
108
12.00 일간 변동폭 12.00
12.00 52주 범위 23.50
market_cap
전일 종가
15.35
개장가
12.00
최근 거래 시간
8
@
10.59
마지막 거래 시간
재정 규모
-
VWAP
-
평균 볼륨(3m)
183
발행 주식
224,708
배당수익률
-
주가수익률
-3.27
주당순이익(EPS)
-4.7
매출
998k
순이익
-1.06M

Helix Biomedix Inc (PK) 정보

Helix BioMedix is a preclinical biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body's innate immunity many of w... Helix BioMedix is a preclinical biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body's innate immunity many of which the company has outlicensed to partners to commercialize. Helix BioMedix, Inc., is committed to building long term shareholder value through development of novel drugs for rare dermatological conditions with unmet needs and strategic management of our diverse peptide library. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
본부
Bothell, USA
설립됨
-
Helix Biomedix Inc (PK) is listed in the Pharmaceutical Preparations sector of the OTC 시장 with ticker HXBM. The last closing price for Helix Biomedix (PK) was US$15.35. Over the last year, Helix Biomedix (PK) shares have traded in a share price range of US$ 12.00 to US$ 23.50.

Helix Biomedix (PK) currently has 224,708 shares in issue. The market capitalisation of Helix Biomedix (PK) is US$3.45 million. Helix Biomedix (PK) has a price to earnings ratio (PE ratio) of -3.27.

HXBM 최신 뉴스

Helix BioMedix Reports Third Quarter 2012 Financial Results

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2012. Third Quarter 2012...

Helix BioMedix Announces Plan for Voluntary Suspension of SEC Reporting Obligations

Helix BioMedix, Inc. (OTCQB: HXBM) (the “Company”), a developer of bioactive peptides, today announced that it has filed a Schedule 13E-3 and related preliminary proxy statement...

Helix BioMedix Reports Second Quarter 2012 Financial Results; Launches New Apothederm™ Acne Clarifying Treatment

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the second quarter ended June 30, 2012. Second Quarter 2012...

Helix BioMedix Reports First Quarter 2012 Financial Results

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the first quarter ended March 31, 2012. First Quarter 2012...

Helix BioMedix Reports Record 2011 Financial Results

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the year ended December 31, 2011. 2011 Financial and Business...

Helix BioMedix Strengthens Intellectual Property Position

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that it has been granted four new U.S. and foreign patents, further strengthening the...

Helix BioMedix Reports Third Quarter 2011 Results

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the company’s third quarter ended September 30, 2011. Third...

Helix BioMedix Reports Another Revenue Record in the Second Quarter 2011

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the company’s second quarter ended June 30, 2011. Second...

Helix BioMedix Develops Anti-Blemish Line for UK’s Premier Skin Care Group sk:n

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced that three new anti-blemish products developed by the company have been launched by sk:n –...

Helix BioMedix Reports Consecutive Record Revenue in the First Quarter 2011

Helix BioMedix, Inc. (OTCQB: HXBM), a developer of bioactive peptides, today announced financial results for the company’s first quarter ended March 31, 2011. First Quarter...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
100012000CS
400012000CS
12-6-33.333333333318181218315.45454545CS
26-11.5-48.936170212823.523.51215317.51383178CS
52-11.27-48.431456811323.2723.51213319.40121859CS
156-9.99999999998E-5-0.00083332638894512.0001261219920.6102671CS
260-29.2-70.873786407841.241.21222224.00222176CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
IBKKFImining Technologies Inc (CE)
US$ 0.05
(4,999,900.00%)
833
WRCDFWirecard AG (CE)
US$ 0.01
(999,900.00%)
250
SLAAFSitios Latinoamerica SAB de CV (PK)
US$ 0.189
(94,400.00%)
21.85k
MIKPMike The Pike Productions Inc (CE)
US$ 0.0002
(19,900.00%)
520k
KBNTKubient Inc (CE)
US$ 0.0002
(19,900.00%)
1.48k
AMHGQAmergent Hospitality Group Inc (CE)
US$ 0.000001
(-100.00%)
76.67k
CLVRClever Leaves Holdings Inc (CE)
US$ 0.000001
(-100.00%)
240
NEPTFNeptune Wellness Solutions Inc (CE)
US$ 0.000001
(-100.00%)
3.72k
ORMTQOrmet Corp (CE)
US$ 0.000001
(-99.99%)
500k
RKIGFReko International Group Inc (PK)
US$ 0.0006
(-99.98%)
100
RDARRaadr Inc (PK)
US$ 0.001
(-28.57%)
320.76M
HMBLHUMBL Inc (PK)
US$ 0.0012
(-4.00%)
311.02M
MMEXMMEX Resources Corporation (PK)
US$ 0.0001
(9,900.00%)
265.88M
EARIEntertainment Arts Research Inc (PK)
US$ 0.0001
(0.00%)
213.32M
CGACCode Green Apparel Corp (PK)
US$ 0.0005
(-16.67%)
125.52M

최근 히스토리

Delayed Upgrade Clock